Author | Kristie L. Kahl


Testosterone levels show steady decrease among young US men

July 03, 2020


The decline in total testosterone was observed even among men with normal body mass index.

Personalized cancer vaccine combo induces clinical benefit in advanced solid tumors

June 22, 2020


The combination of the personalized cancer vaccine RO719845 and the PD-L1 inhibitor atezolizumab showed strong clinical activity across solid tumors, including bladder cancer and renal cell carcinoma.

Exceeding exercise guidelines may reduce likelihood of low T in men

May 27, 2020


Men whose activity exceeded guideline-based exercise levels experienced a decreased likelihood of lower serum testosterone, according to study results presented at the American Urological Association 2020 Virtual Experience.

Further Evaluation of Tivozanib Shows Promise for Relapsed, Refractory Renal Cell Carcinoma

May 19, 2020


Results from the phase III TIVO-3 trial of tivozanib (Fotivda) demonstrated a statistically significant improvement in median progression-free survival compared with sorafenib (Sutent), as well as favorable tolerability, in patients with relapsed or refractory renal cell carcinoma.